These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21525868)

  • 1. Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan.
    Lin TC; Yang CY; Yang YH; Lin SJ
    Clin Pharmacol Ther; 2011 Jul; 90(1):109-16. PubMed ID: 21525868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan.
    Chen YJ; Kung PT; Chou WY; Tsai WC
    Osteoporos Int; 2020 Aug; 31(8):1555-1563. PubMed ID: 32221674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
    Lin TC; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low incidence of anti-osteoporosis treatment after hip fracture.
    Rabenda V; Vanoverloop J; Fabri V; Mertens R; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    J Bone Joint Surg Am; 2008 Oct; 90(10):2142-8. PubMed ID: 18829912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.
    Rabenda V; Mertens R; Fabri V; Vanoverloop J; Sumkay F; Vannecke C; Deswaef A; Verpooten GA; Reginster JY
    Osteoporos Int; 2008 Jun; 19(6):811-8. PubMed ID: 17999022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.
    Siris ES; Harris ST; Rosen CJ; Barr CE; Arvesen JN; Abbott TA; Silverman S
    Mayo Clin Proc; 2006 Aug; 81(8):1013-22. PubMed ID: 16901023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
    Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
    Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature.
    Iwamoto J; Sato Y; Takeda T; Matsumoto H
    Clin Interv Aging; 2008; 3(3):483-9. PubMed ID: 18982918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.
    Curtis JR; Delzell E; Chen L; Black D; Ensrud K; Judd S; Safford MM; Schwartz AV; Bauer DC
    J Bone Miner Res; 2011 Apr; 26(4):683-8. PubMed ID: 20939064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
    Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
    Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
    Bize R; Lamy O; Peytremann-Bridevaux I
    Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
    [No Abstract]   [Full Text] [Related]  

  • 13. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
    Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
    Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hip and subtrochanteric or diaphyseal femoral fractures in alendronate users: a 10-year, nationwide retrospective cohort study in Taiwanese women.
    Hsiao FY; Huang WF; Chen YM; Wen YW; Kao YH; Chen LK; Tsai YW
    Clin Ther; 2011 Nov; 33(11):1659-67. PubMed ID: 22018450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
    Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
    J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG; Reddy S
    Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan.
    Soong YK; Tsai KS; Huang HY; Yang RS; Chen JF; Wu PC; Huang KE
    Osteoporos Int; 2013 Feb; 24(2):511-21. PubMed ID: 22588182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
    Saag KG; Petersen J; Brandi ML; Karaplis AC; Lorentzon M; Thomas T; Maddox J; Fan M; Meisner PD; Grauer A
    N Engl J Med; 2017 Oct; 377(15):1417-1427. PubMed ID: 28892457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alendronate and risk of lower limb ischemic vascular events: a population-based cohort study.
    Chen CK; Chang HT; Chou HP; Lee MH; Chen YC; Huang YC; Chen TJ; Chang HL; Shih CC
    Osteoporos Int; 2014 Feb; 25(2):673-80. PubMed ID: 23943167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.
    Curtis JR; Westfall AO; Cheng H; Delzell E; Saag KG
    Osteoporos Int; 2008 Nov; 19(11):1613-20. PubMed ID: 18483689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.